Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 18 | 2022 | 55 | 2.970 |
Why?
|
| Antidepressive Agents | 15 | 2022 | 48 | 1.900 |
Why?
|
| Depressive Disorder | 14 | 2003 | 90 | 1.180 |
Why?
|
| Psychiatric Status Rating Scales | 17 | 2020 | 132 | 0.750 |
Why?
|
| Tetrahydrofolates | 3 | 2016 | 3 | 0.680 |
Why?
|
| Antidepressive Agents, Second-Generation | 6 | 2010 | 11 | 0.570 |
Why?
|
| Treatment Outcome | 21 | 2022 | 1478 | 0.530 |
Why?
|
| Double-Blind Method | 15 | 2016 | 166 | 0.470 |
Why?
|
| Secondary Prevention | 9 | 2020 | 25 | 0.450 |
Why?
|
| Humans | 39 | 2022 | 12240 | 0.430 |
Why?
|
| Fluoxetine | 6 | 2005 | 13 | 0.410 |
Why?
|
| Triazoles | 3 | 2002 | 14 | 0.380 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 1997 | 20 | 0.370 |
Why?
|
| Depression | 2 | 2022 | 229 | 0.370 |
Why?
|
| Folic Acid | 1 | 2011 | 15 | 0.340 |
Why?
|
| Cyclohexanols | 5 | 2010 | 9 | 0.340 |
Why?
|
| Bipolar Disorder | 5 | 2007 | 47 | 0.330 |
Why?
|
| Adult | 21 | 2016 | 3557 | 0.320 |
Why?
|
| Acetamides | 1 | 2010 | 2 | 0.310 |
Why?
|
| Male | 26 | 2020 | 6815 | 0.310 |
Why?
|
| Female | 25 | 2020 | 6974 | 0.300 |
Why?
|
| Drug Therapy, Combination | 5 | 2016 | 76 | 0.270 |
Why?
|
| Middle Aged | 14 | 2020 | 4043 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2015 | 179 | 0.260 |
Why?
|
| Drug Administration Schedule | 11 | 2007 | 84 | 0.250 |
Why?
|
| Piperazines | 5 | 2015 | 41 | 0.240 |
Why?
|
| Surveys and Questionnaires | 4 | 2015 | 546 | 0.200 |
Why?
|
| Aged | 10 | 2016 | 4000 | 0.200 |
Why?
|
| Young Adult | 4 | 2016 | 863 | 0.200 |
Why?
|
| Personality Inventory | 2 | 2000 | 31 | 0.190 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2022 | 4 | 0.180 |
Why?
|
| Obsessive-Compulsive Disorder | 3 | 2006 | 11 | 0.180 |
Why?
|
| Remission Induction | 4 | 2020 | 45 | 0.180 |
Why?
|
| Adolescent | 7 | 2015 | 989 | 0.170 |
Why?
|
| Acute Disease | 4 | 2013 | 90 | 0.170 |
Why?
|
| Anxiety Disorders | 2 | 2002 | 84 | 0.160 |
Why?
|
| Sertraline | 3 | 2006 | 9 | 0.160 |
Why?
|
| Recurrence | 2 | 2016 | 126 | 0.150 |
Why?
|
| Quality of Life | 3 | 2010 | 261 | 0.140 |
Why?
|
| Long-Term Care | 2 | 2016 | 24 | 0.140 |
Why?
|
| Antipsychotic Agents | 3 | 2003 | 29 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 128 | 0.130 |
Why?
|
| Venlafaxine Hydrochloride | 5 | 2010 | 8 | 0.120 |
Why?
|
| Serotonin | 2 | 1997 | 14 | 0.110 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 143 | 0.110 |
Why?
|
| Placebos | 4 | 2006 | 25 | 0.110 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2007 | 4 | 0.110 |
Why?
|
| Sulfides | 1 | 2015 | 4 | 0.110 |
Why?
|
| Anti-Anxiety Agents | 1 | 2015 | 15 | 0.110 |
Why?
|
| Patient Compliance | 4 | 2007 | 75 | 0.110 |
Why?
|
| S-Adenosylhomocysteine | 1 | 2014 | 1 | 0.110 |
Why?
|
| Aldehydes | 1 | 2014 | 2 | 0.110 |
Why?
|
| S-Adenosylmethionine | 1 | 2014 | 3 | 0.110 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2014 | 3 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 151 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 54 | 0.100 |
Why?
|
| Vagus Nerve | 2 | 2022 | 9 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2016 | 817 | 0.100 |
Why?
|
| Pirenzepine | 2 | 2003 | 3 | 0.100 |
Why?
|
| Valproic Acid | 2 | 2003 | 7 | 0.100 |
Why?
|
| Anticonvulsants | 2 | 2003 | 30 | 0.100 |
Why?
|
| Prevalence | 1 | 2013 | 175 | 0.090 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2004 | 8 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 17 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2015 | 437 | 0.090 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 1991 | 4 | 0.080 |
Why?
|
| Patient Education as Topic | 2 | 2003 | 64 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2006 | 423 | 0.080 |
Why?
|
| Orgasm | 1 | 1991 | 7 | 0.080 |
Why?
|
| Patient Selection | 1 | 2011 | 111 | 0.080 |
Why?
|
| Social Adjustment | 1 | 2010 | 11 | 0.080 |
Why?
|
| Duloxetine Hydrochloride | 2 | 2015 | 3 | 0.080 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 5 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 726 | 0.080 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2000 | 45 | 0.070 |
Why?
|
| Ambulatory Care | 3 | 2003 | 36 | 0.070 |
Why?
|
| Nausea | 2 | 1999 | 16 | 0.070 |
Why?
|
| Sleep Stages | 2 | 1999 | 12 | 0.070 |
Why?
|
| Ribavirin | 1 | 2007 | 3 | 0.060 |
Why?
|
| Interferon-alpha | 1 | 2007 | 15 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2007 | 27 | 0.060 |
Why?
|
| Half-Life | 2 | 1997 | 7 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 18 | 0.060 |
Why?
|
| Syndrome | 2 | 1997 | 40 | 0.060 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2004 | 5 | 0.060 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 58 | 0.060 |
Why?
|
| Hypericum | 1 | 2005 | 1 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2005 | 8 | 0.060 |
Why?
|
| Electric Stimulation Therapy | 1 | 2005 | 18 | 0.060 |
Why?
|
| Thiophenes | 1 | 2004 | 7 | 0.050 |
Why?
|
| Comorbidity | 3 | 2002 | 209 | 0.050 |
Why?
|
| Morpholines | 1 | 2003 | 7 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2002 | 186 | 0.050 |
Why?
|
| Paroxetine | 2 | 2007 | 7 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2003 | 15 | 0.050 |
Why?
|
| Weight Gain | 2 | 2000 | 30 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 116 | 0.040 |
Why?
|
| Thiazoles | 1 | 2001 | 8 | 0.040 |
Why?
|
| Psychomotor Agitation | 1 | 2001 | 5 | 0.040 |
Why?
|
| Health Status | 2 | 2003 | 96 | 0.040 |
Why?
|
| Telephone | 1 | 2000 | 12 | 0.040 |
Why?
|
| Psychotic Disorders | 1 | 2001 | 20 | 0.040 |
Why?
|
| Psychometrics | 1 | 2000 | 95 | 0.040 |
Why?
|
| Asthenia | 1 | 2000 | 1 | 0.040 |
Why?
|
| Desipramine | 1 | 2000 | 1 | 0.040 |
Why?
|
| Feeding and Eating Disorders | 1 | 2000 | 6 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 252 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2000 | 46 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2000 | 324 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2000 | 55 | 0.040 |
Why?
|
| Body Weight | 1 | 1999 | 72 | 0.040 |
Why?
|
| Headache | 1 | 1999 | 22 | 0.040 |
Why?
|
| Delayed-Action Preparations | 2 | 2010 | 18 | 0.040 |
Why?
|
| Anxiety | 1 | 1999 | 73 | 0.040 |
Why?
|
| Abbreviations as Topic | 1 | 1997 | 1 | 0.030 |
Why?
|
| Paresthesia | 1 | 1997 | 2 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 1997 | 8 | 0.030 |
Why?
|
| Receptors, Serotonin | 1 | 1997 | 10 | 0.030 |
Why?
|
| Neurotransmitter Agents | 1 | 1997 | 7 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1997 | 11 | 0.030 |
Why?
|
| Life Change Events | 1 | 1997 | 21 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1997 | 19 | 0.030 |
Why?
|
| Dizziness | 1 | 1997 | 9 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 13 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1997 | 46 | 0.030 |
Why?
|
| Primary Health Care | 1 | 1997 | 35 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2006 | 20 | 0.030 |
Why?
|
| Incidence | 1 | 1997 | 338 | 0.030 |
Why?
|
| Genotype | 1 | 2014 | 169 | 0.030 |
Why?
|
| Risk Factors | 1 | 1997 | 1049 | 0.020 |
Why?
|
| Benzodiazepines | 2 | 2003 | 21 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 558 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 294 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 40 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 1991 | 2 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1991 | 16 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 1991 | 13 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 1990 | 3 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 651 | 0.020 |
Why?
|
| Outpatients | 1 | 2007 | 24 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 60 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2007 | 112 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2005 | 12 | 0.010 |
Why?
|
| Plant Extracts | 1 | 2005 | 6 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2005 | 13 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 125 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 103 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2005 | 256 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2003 | 99 | 0.010 |
Why?
|
| Health Services | 1 | 2003 | 4 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2003 | 32 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 118 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2001 | 6 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 2001 | 11 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2001 | 39 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2001 | 27 | 0.010 |
Why?
|
| Appetite | 1 | 1999 | 3 | 0.010 |
Why?
|
| Weight Loss | 1 | 1999 | 78 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1999 | 221 | 0.010 |
Why?
|